Increased Production of the Soluble Tumor-Associated Antigens CA19-9, CA125, and CA15-3 in Rheumatoid Arthritis
dc.contributor.author | Szekanecz, Éva | en_US |
dc.contributor.author | Sándor, Zsuzsa | en_US |
dc.contributor.author | Antal-Szalmás, Péter | en_US |
dc.contributor.author | Soós, Lilla | en_US |
dc.contributor.author | Lakos, Gabriella | en_US |
dc.contributor.author | Besenyei, Timea | en_US |
dc.contributor.author | Szentpétery, Ágnes | en_US |
dc.contributor.author | Simkovics, Enikö | en_US |
dc.contributor.author | Szántó, János | en_US |
dc.contributor.author | Kiss, Emese | en_US |
dc.contributor.author | Koch, Alisa E. | en_US |
dc.contributor.author | Szekanecz, Zoltán | en_US |
dc.date.accessioned | 2010-06-01T20:05:56Z | |
dc.date.available | 2010-06-01T20:05:56Z | |
dc.date.issued | 2007-06 | en_US |
dc.identifier.citation | SZEKANECZ, ÉVA; SÁNDOR, ZSUZSA; ANTAL-SZALMÁS, PÉTER; SOÓS, LILLA; LAKOS, GABRIELLA; BESENYEI, TIMEA; SZENTPÉTERY, ÁGNES; SIMKOVICS, ENIKÖ; SZÁNTÓ, JÁNOS; KISS, EMESE; KOCH, ALISA E.; SZEKANECZ, ZOLTÁN (2007). "Increased Production of the Soluble Tumor-Associated Antigens CA19-9, CA125, and CA15-3 in Rheumatoid Arthritis." Annals of the New York Academy of Sciences 1108(1 Autoimmunity, Part D: Autoimmune Disease, Annus Mirabilis ): 359-371. <http://hdl.handle.net/2027.42/73224> | en_US |
dc.identifier.issn | 0077-8923 | en_US |
dc.identifier.issn | 1749-6632 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/73224 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17893999&dopt=citation | en_US |
dc.description.abstract | Some tumor-associated antigens (TAAs) are expressed on inflammatory cells. We previously detected carcinoembryonic antigen (CEA; CD66) in the rheumatoid (RA) synovium. The production of CEA, CA19-9, CA125, and CA15.3, may be increased in patients with RA, scleroderma, lupus, and SjÖgren's syndrome (SS). Some of these TAAs contain sialylated carbohydrate motifs and they are involved in tumor-associated cell adhesion and metastasis. We assessed levels of TAAs in the sera of RA patients and healthy subjects. Serum TAA levels were correlated with disease markers including serum rheumatoid factor (RF), C-reactive protein (CRP), and anti-CCP antibody levels, DAS28, age disease duration. TAAs including CEA, CA15-3, CA72-4, CA125, and CA19-9, and neuron-specific enolase (NSE) were assessed by immunoassay in the sera of 75 patients with RA and 50 age- and sex-matched healthy controls. Normal upper limits for these TAAs were 3.4 Μg/L, 25 kU/L, 6.9 kU/L, 35 kU/L, 34 kU/L, and 16.3 Μg/L, respectively. There were significantly more RA patients showing abnormally high levels of CA125 (10.8% versus 7.1%), CA19-9 (8.1% versus 0%), and CA15-3 (17.6% versus 14.3%) in comparison to controls ( P < 0.05). The mean absolute serum levels of CA125 (23.9 ± 1.8 versus 16.8 ± 2.2 kU/L) and CA19-9 (14.2 ± 1.2 versus 10.5 ± 1.6 kU/L) were also significantly higher in RA compared to controls ( P < 0.05). Among RA patients, serum CEA showed significant correlation with RF ( r = 0.270; P < 0.05). None of the assessed TAAs showed any correlation with CRP, anti-CCP, DAS28, age or disease duration. The concentration of some TAAs may be elevated in the sera of patients with established RA in comparison to healthy subjects. CEA, CA19-9, CA125, and CA15-3 contain carbohydrate motifs and thus they may be involved in synovitis-associated adhesive events. Furthermore, some TAAs, such as CEA, may also correlate with prognostic factors, such as serum RF levels. | en_US |
dc.format.extent | 203699 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Inc | en_US |
dc.rights | 2007 New York Academy of Sciences | en_US |
dc.subject.other | Rheumatoid Arthritis | en_US |
dc.subject.other | Tumor Antigens | en_US |
dc.subject.other | Anti-CCP Antibody | en_US |
dc.subject.other | Rheumatoid Factor | en_US |
dc.subject.other | Carcinoembryonic Antigen | en_US |
dc.title | Increased Production of the Soluble Tumor-Associated Antigens CA19-9, CA125, and CA15-3 in Rheumatoid Arthritis | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Science (General) | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Health System, Department of Internal Medicine, Division of Rheumatology, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | Department of Oncology, University of Debrecen Medical and Health Science Center, Debrecen, Hungary | en_US |
dc.contributor.affiliationother | Rheumatology Division, University of Debrecen Medical and Health Science Center, Debrecen, Hungary | en_US |
dc.contributor.affiliationother | Department of Pathology, University of Debrecen Medical and Health Science Center, Debrecen, Hungary | en_US |
dc.contributor.affiliationother | Department of Clinical Biochemistry and Molecular Pathology, Third Department of Medicine, University of Debrecen Medical and Health Science Center, Debrecen, Hungary | en_US |
dc.contributor.affiliationother | Laboratory of Immunology, University of Debrecen Medical and Health Science Center, Debrecen, Hungary | en_US |
dc.identifier.pmid | 17893999 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/73224/1/annals.1422.037.pdf | |
dc.identifier.doi | 10.1196/annals.1422.037 | en_US |
dc.identifier.source | Annals of the New York Academy of Sciences | en_US |
dc.identifier.citedreference | Harris, E.D., Jr. 1991. Rheumatoid arthritis: pathophysiology and implications for therapy. N. Engl. J. Med. 332: 1277 – 1287. | en_US |
dc.identifier.citedreference | Visser, H., L.B. Gelinck, A.H. Kampfraath, et al. 1996. Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assay in rheumatoid arthritis. Ann. Rheum. Dis. 55: 157 – 161. | en_US |
dc.identifier.citedreference | Pepys, M.B. 1983. C-reactive protein: the role of an ancient protein in modern rheumatology. Clin. Exp. Rheumatol. 1: 3 – 7. | en_US |
dc.identifier.citedreference | Schellenkens, G.A., B.A.W. de Jong, F.H.J. Van Den Hoogen, et al. 1998. Citrulline is an essential constituent of antigenic determinants recognised by rheumatoid arthritis–specific autoantibodies. J. Clin. Invest. 101: 273 – 281. | en_US |
dc.identifier.citedreference | Mediwake, R., D.A. Isenberg, G.A. Schellekens & W.J. van Venrooij. 2001. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann. Rheum. Dis. 60: 67 – 68. | en_US |
dc.identifier.citedreference | Forsind, K., M. AhlmÉn, K. Eberhardt, et al. 2004. Prediction of radiological outcome in early rheumatoid arthritis in a clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann. Rheum. Dis. 63: 1090 – 1095. | en_US |
dc.identifier.citedreference | Zeng, X., M. Ai, X. Tian, et al. 2003. Diagnostic value of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. J. Rheumatol. 30: 1451 – 1455. | en_US |
dc.identifier.citedreference | Bongi, S.M., R. Manetti, D. Melchiorre, et al. 2004. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis anti-CCP and bone damage in RA. Autoimmunity 37: 495 – 501. | en_US |
dc.identifier.citedreference | Szekanecz, Z., G.K. Haines, L.A. Harlow, et al. 1995. Increased synovial expression of the adhesion molecules CD66a, CD66b and CD31 in rheumatoid and osteoarthritis. Clin. Immunol. Immunopathol. 76: 180 – 186. | en_US |
dc.identifier.citedreference | Cantagrel, A., L. Moulinier, K. Beljio, et al. 1994. Increase of CA 19.9 in dysimmune inflammatory rheumatism. Apropos of 6 cases. Rev. Rhum. Ed. Fr. 61: 599 – 606. | en_US |
dc.identifier.citedreference | Rump, A., Y. Morikawa, M. Tanaka, et al. 2004. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem. 279: 9190 – 9198. | en_US |
dc.identifier.citedreference | Duffy, M.J., S. Shering, F. Sherry, et al. 2000. CA 15-3, a prognostic marker in breast cancer. Int. J. Biol. Markers 15: 330 – 333. | en_US |
dc.identifier.citedreference | Williams, A.F. & A.N. Barclay. 1988. The immunoglobulin superfamily. Domains for cell surface recognition. Annu. Rev. Immunol. 6: 381 – 405. | en_US |
dc.identifier.citedreference | Lance, M.P. 1990. CEA as a cell adhesion molecule. Gastroenterology 99: 277 – 278. | en_US |
dc.identifier.citedreference | Kuijpers, T.W., M. Hoogerwerf, L.J. Van Der Laan, et al. 1992. CD66 nonspecific cross-reacting antigens are involved in neutrophil adherence to cytokine-activated endothelial cells. J. Cell. Biol. 118: 457 – 466. | en_US |
dc.identifier.citedreference | Stocks, S.C. & M.A. Kerr. 1992. Neutrophil NCA-160 (CD66) is the major protein carrier of selectin binding carbohydrate groups LewisX and sialyl lewisX. Biochem. Biophys. Res. Commun. 195: 478 – 483. | en_US |
dc.identifier.citedreference | Audette, M., F. Buchegger, M. Schreyer & J.P. Mach. 1987. Monoclonal antibody against carcinoembryonic antigen (CEA) identifies two new forms of crossreacting antigens of molecular weights 90,000 and 160,000 in normal granulocytes. Mol. Immunol. 24: 1177 – 1186. | en_US |
dc.identifier.citedreference | Ducker, T.P. & K.M. Skubitz. 1992. Subcellular localization of CD66, CD67, and NCA in human neutrophils. J. Leuk. Biol. 52: 11 – 16. | en_US |
dc.identifier.citedreference | Torsteinsdottir, I., N.G. Arvidson, R. Hallgren & L. Hakansson. 1999. Enhanced expression of integrins and CD66b on peripheral blood neutrophils and eosinophils in patients with rheumatoid arthritis and the effect of glucocorticoids. Scand. J. Immunol. 50: 433 – 439. | en_US |
dc.identifier.citedreference | Benchimol, S., A. Fuks, S. Jothy, et al. 1989. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57: 327 – 334. | en_US |
dc.identifier.citedreference | Unger, A., G.S. Panayi & M.H. Lessof. 1975. Carcinoembryonic antigen in rheumatic diseases. Rheumatol. Rehabil. 14: 19 – 24. | en_US |
dc.identifier.citedreference | Shimomura, C., K. Eguchi, A. Kawakami, et al. 1989. Elevation of tumor associated antigen CA 19-9 levels in patients with rheumatic diseases. J. Rheumatol. 16: 1410 – 1415. | en_US |
dc.identifier.citedreference | Kimura, K., K. Ezoe, H. Yokozeki, et al. 1995. Elevated serum CA125 in progressive systemic sclerosis with pleural effusion. J. Dermatol. 22: 28 – 31. | en_US |
dc.identifier.citedreference | Valerio-Marzano, A., A. Morabito, E. Berti & R. Caputo. 1998. Elevated circulating CA 15.3 levels in a subset of systemic sclerosis with severe lung involvement. Arch. Dermatol. 34: 645. | en_US |
dc.identifier.citedreference | Takeda, N., H. Ihn & S. Teramoto. 2001. Markedly increased levels of IL-6 and CA125 in pleural fluids of an elderly person with overlap syndrome of systemic sclerosis and systemic lupus erythematosus. Age Ageing 30: 171. | en_US |
dc.identifier.citedreference | Safadi, R., M. Ligumsky, E. Goldin, et al. 1998. Increased serum CA 19-9 antibodies in SjÖgren's syndrome. Postgrad. Med. J. 74: 543 – 544. | en_US |
dc.identifier.citedreference | Fabris, C., E. Falleti, M. Pirisi, et al. 1995. Non-specific increase of serum carbohydrate antigen 19-9 in patients with liver disease associated with increased circulating levels of adhesion molecules. Clin. Chim. Acta 243: 25 – 33. | en_US |
dc.identifier.citedreference | Rahn, J.J., J.W. Chow, G.J. Horne, et al. 2005. MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin. Exp. Metastasis 22: 475 – 483. | en_US |
dc.identifier.citedreference | Dettke, M., G. Palfi, E. Pursch, et al. 2001. Increased expression of the blood group-related Lewis-Y antigen on synovial fluid granulocytes of patients with arthritic joint diseases. Rheumatology 40: 1033 – 1077. | en_US |
dc.identifier.citedreference | Halloran, M.M., W.W. Carley, P.J. Polverini, et al. 2000. Ley/H: an endothelial-selective, cytokine-inducible angiogenic mediator. J. Immunol. 164: 4868 – 4877. | en_US |
dc.identifier.citedreference | Koch, A.E., J.C. Burrows, G.K. Haines, et al. 1991. Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues. Lab Invest. 64: 313 – 320. | en_US |
dc.identifier.citedreference | Seelenmeyer, C., S. Wegehingel, J. Lechner & W. Nickel. 2003. The cancer antigen CA125 represents a novel counter receptor for galectin-1. J. Cell. Sci. 116: 1305 – 1318. | en_US |
dc.identifier.citedreference | Correa, I., T. Plunkett, A. Vlad, et al. 2003. Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T cell migration. Immunology 108: 32 – 41. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.